Clinical trials: Human Immunodeficiency Viruses
HIV Infections
Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine
A vaccine to prevent infection with the Human Immunodeficiency Virus (HIV) is urgently needed. Worldwide, most HIV infections occur through sex between a man and woman.
- Trial name
- TL01 (NCT01285141)
- Testing
- CN54gp140 glycoprotein-hsp70 conjugate vaccine
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Infections, Mental Health
BEYOND Study: Improving HIV Treatment and Well-Being Among Young MSM in Vietnam
The BEYOND Study aims to evaluate HIV treatment outcomes and well-being among young men who have sex with men (YMSM) living with HIV in Ho Chi Minh City, Vietnam.
- Conditions
- HIV Infections, Mental Health, Medication Adherence
- Trial name
- BEYOND (NCT07559266)
- Testing
- NO interventions listed
- Where
- Vietnam
- Volunteers
- 300 people
- Sponsor
- Center for Applied Research on Men and Community Health, Vietnam
Sexually Transmitted Infections
Brief HIV Prevention Counseling for STI Patients in South Africa
This is a randomized trial to test a brief single session risk reduction counseling intervention on HIV and STI behavioral outcomes in Cape Town South Africa.
- Trial name
- NCT01242501
- Testing
- 60 Minute HIV/STI risk reduction counseling.Single 60 min Social Cognitive Theory-based counseling., 20-Min education session
- Where
- United States
- Volunteers
- 1,050 people
- Sponsor
- University of Connecticut
HIV Infections
Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure
The primary objective was to determine the mean change in HIV viral load from baseline to Week 4 compared with placebo after 4 weeks of treatment in highly experienced HIV-infected patients.
- Trial name
- NCT02232581
- Testing
- Alovudine - low, Alovudine - medium, Alovudine - high
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
HIV/AIDS
Effect of U=U Messaging on HIV in South Africa
This cluster randomized trial will investigate whether messaging about being undetectable equals untransmittable (U=U) designed through a participatory, user-centered approach increases HIV testing uptake within men in…
- Trial name
- U=U (NCT04364165)
- Testing
- Standard invitation to free HIV testing at mobile clinic, U=U messaging and invitation to free HIV testing at mobile clinic
- Where
- South Africa
- Volunteers
- 1,048 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
AIDS Dementia Complex, HIV Infections
A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)
The purpose of this study is to determine the safety and effectiveness of memantine, an experimental drug, in improving AIDS dementia complex (ADC). The symptoms of ADC can be improved with zidovudine (ZDV).
- Trial name
- NCT00000867
- Testing
- Memantine
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anal Neoplasm
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
This is a phase 2, open-label efficacy study of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) in adult men and women who are human immunodeficiency virus (HIV) negative with histologically…
- Trial name
- NCT03499795
- Testing
- VGX-3100, CELLECTRA™ 5PSP
- Where
- 3 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- Inovio Pharmaceuticals
Human Immunodeficiency Virus, Herpes Simplex Type II
MAMAS: Mentoring Adolescent Mothers at School
This study aims to evaluate the efficacy of an intervention designed to reduce STI/HIV incidence by increasing the number of adolescent mothers who re-enroll and remain in school.
- Conditions
- Human Immunodeficiency Virus, Herpes Simplex Type II, Chlamydia, Gonorrhea
- Trial name
- MAMAS (NCT03090802)
- Testing
- Mentoring Adolescent Mothers at School (MAMAS)
- Where
- South Africa
- Volunteers
- 152 people
- Sponsor
- Drexel University
HIV Infection
Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults
This is a randomized, open label, phase II trial to evaluate the safety and immunogenicity of two different schedules of vaccination against influenza A H1N1 in HIV-infected individuals, in which each of the randomized groups…
- Trial name
- VIP-H1N1 (NCT01155037)
- Testing
- Adjuvanted vaccine against H1N1 influenza virus (GSK)
- Where
- Brazil
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV Infections
The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects
The purpose of this study is to investigate the possibility of an association between changes in neurocognitive function, as measured by a computerised test battery, and the use of two different highly active antiretroviral…
- Trial name
- NCT00540137
- Testing
- nevirapine, atazanavir/ritonavir
- Where
- 2 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- Imperial College London
HIV Infection
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1:FOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC (MARAVI-PEP)
As a measure of secondary prophylaxis, and with the final objective of avoiding the infection, it has been suggested to use antiretroviral therapy. This is known as post-exposure prophylaxis (PEP).
- Trial name
- NCT01533272
- Testing
- Tenofovir, emtricitabine, maraviroc, Tenofovir, emtricitabine, lopinavir/r
- Where
- Spain
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Tuberculosis
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents
This observer blind study will assess the safety and immunogenicity of GSK Biologicals' investigational 692342 vaccine administered at 0, 1 month to healthy adolescents living in a TB-endemic region.
- Trial name
- NCT00950612
- Testing
- GSK's investigational vaccine 692342
- Where
- South Africa
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
The purpose of this study is to evaluate the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with an experimental modified vaccinia HIV vaccine (MVA) in HIV uninfected adults.
- Trial name
- NCT00574600
- Testing
- SAAVI DNA-C2 vaccine, SAAVI MVA-C vaccine
- Where
- 4 sites in United States, South Africa
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV
Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention
This project called Mobile Technology and Incentives (MOTIVES) aims to increase engagement with HIV prevention information and improve testing frequency among Latino/a men who have sex with men (MSM) and transgender women (TGW).
- Trial name
- MOTIVES (NCT03144336)
- Testing
- Information provision, Weekly quizzes, Rewards for testing HIV-negative
- Where
- United States
- Volunteers
- 217 people
- Sponsor
- RAND
HPV Infection, Cervical Cancer
HPV-Based Screen-and-Treat Demonstration Project in Lilongwe
The purpose of this study is to assess completion and performance of the following novel invasive cervical cancer (ICC) screen-and-treat algorithm among 625 HIV-positive women in Lilongwe, Malawi: 1) rapid testing of…
- Conditions
- HPV Infection, Cervical Cancer, HIV Infections
- Trial name
- NCT04092257
- Testing
- VIA and thermocoagulation
- Where
- Malawi
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced HIV Disease
Advanced HIV Re-engagement in Care
Adults who are hospitalized in Lusaka, Zambia, and found to have advanced HIV disease will be enrolled and randomly assigned to receive the ARC intervention or standard of care.
- Trial name
- ARC (NCT07720128)
- Testing
- ARC
- Where
- Zambia
- Volunteers
- 724 people
- Sponsor
- University of Alabama at Birmingham
HIV, Sexually Transmitted Diseases
Web-Based Middle School HIV Prevention Curricula: Aspiring for Reach and Impact
The purpose of this study is to evaluate the effectiveness of a web-based HIV, sexually transmitted infection (STI), and pregnancy prevention curriculum as a stand alone intervention for 8th grade students in a large urban school…
- Trial name
- NCT01280136
- Testing
- It's Your Game Tech
- Where
- United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
HIV
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.
A prospective, open, multicenter,demonstrative of PrEP, which aims to assess the acceptability, feasibility and safety from chemoprophylaxis co-formulated emtricitabine / tenofovir disoproxil fumarate (FTC / TDF) administered…
- Trial name
- PrEPBrasil (NCT01989611)
- Testing
- emtricitabine / tenofovir 200/300 mg
- Where
- 3 sites in Brazil
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Oswaldo Cruz Foundation
HIV Infections
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.
- Trial name
- NCT00002129
- Testing
- Vesnarinone
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Otsuka America Pharmaceutical
Hepatitis B, Hepatitis C
Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
MaHeVi is a multicenter, cross-sectional, population-based study which will include 2500 adults in the health care centers / missions located on the 2 sides of the Maroni River.
- Conditions
- Hepatitis B, Hepatitis C, Hepatitis D, HIV Infections
- Trial name
- MaHeVi (NCT05002907)
- Testing
- Questionnaire, Biocollection, Delivery of results
- Where
- 2 sites in French Guiana, Suriname
- Volunteers
- 2,289 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.